NCT03980002 2019-06-10
BDHCLL001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
Clinical Trials
4 trialsNCT00103558 2015-10-02
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Biogen
Phase 1/2 Completed
NCT00391066 2015-10-02
LUCID
Biogen
Phase 2 Terminated
NCT00801060 2015-10-02
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biogen
Phase 2 Terminated